Rett Syndrome (RTT) Clinical Trials and Treatments

Rett syndrome is a rare X-linked dominant neurodevelopmental disorder caused by mutations in the MECP2 gene, which encodes methyl-CpG-binding protein 2 (MeCP2), essential for normal brain development and function. Infants with Rett syndrome develop normally for the first 6-18 months, achieving normal developmental milestones. Developmental regression then occurs, characterized by loss of purposeful hand skills (replaced by stereotypic hand movements like hand wringing, hand clapping, or hand-to-mouth movements), loss of language and communication abilities, autistic-like behaviors, and progressive motor problems including ataxia, apraxia, and gait abnormalities.

The most common symptoms of Rett Syndrome include Developmental regression around age 6-18 months, Loss of purposeful hand skills and replacement with repetitive hand stereotypies, Loss of language and communication skills, Ataxia, gait abnormalities, and movement disorders, Seizures at some point in life for most people, with lifetime risk near 90%, among others. Rett Syndrome affects approximately 1 in 9,000 to 15,000 girls. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Rett Syndrome from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Rett syndrome research includes gene therapy approaches targeting MECP2 mutations and symptomatic therapies addressing seizures and movement problems. Trofinetide (Daybue), taken twice a day by mouth or through a feeding tube, became the first FDA-approved treatment for Rett syndrome in March 2023, for adults and children 2 years and older.

Yes. As of October 21, 2026, 1 FDA-approved medicine has a current label that names Rett Syndrome: Daybue (trofinetide), first approved in 2023. Corticosteroids and immune globulins count once each.

Rett syndrome is caused by de novo mutations in the MECP2 gene, which encodes methyl-CpG binding protein 2, a critical regulator of gene expression in the brain. MECP2 functions primarily as a transcriptional repressor (and in some contexts an activator), affecting thousands of downstream genes involved in neuronal maturation, synaptic function, and dendritic branching. Because MECP2 is on the X chromosome, Rett almost exclusively affects females. Males with MECP2 mutations typically have severe neonatal encephalopathy, though rare exceptions exist in cases of somatic mosaicism or Klinefelter syndrome (47,XXY). Random X-inactivation means each cell expresses either the normal or mutant copy, creating a mosaic pattern that partly explains the wide spectrum of severity among patients with identical mutations.

Rett syndrome is caused by mutations in the MECP2 gene on the X chromosome in approximately 95% of classic cases. Genetic testing through MECP2 sequencing is the standard confirmatory test and is required for most gene therapy clinical trials. Common pathogenic mutations include R255X, R270X, R168X, R133C, R294X, and T158M, with genotype-phenotype correlations influencing severity. CDKL5 and FOXG1 variants, previously classified as atypical Rett, are now recognized as separate conditions with their own clinical trial pipelines. Labs offering MECP2 testing include GeneDx, Invitae, and Prevention Genetics. X-inactivation patterns can also affect phenotype variability.

Eligibility for Rett Syndrome clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Rett Syndrome clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.

Many Rett syndrome clinical trials ask that seizure medicines stay at a steady dose for a set time before enrollment rather than stopping them, and some exclude specific drugs. The NGN-401 gene therapy trial (NCT05898620), for example, required a seizure medicine regimen that had been stable for at least 12 weeks and did not take people currently on trofinetide (Daybue). Trial Friend's medication conflict checker scans each trial's exclusion criteria against common Rett treatments including trofinetide (Daybue), anti-seizure medications like levetiracetam (Keppra), valproic acid (Depakote), lamotrigine (Lamictal), and clobazam (Onfi), as well as sleep aids and behavioral medications. The checker flags the specific drug, the trial's exclusion language, and a confidence level so you can review options with your daughter's neurologist.

Key questions for your daughter's doctor about Rett clinical trials include: Does her specific MECP2 mutation affect which gene therapy trials she qualifies for? Can she participate while continuing seizure medications like Keppra or Depakote? Are there trials that accept patients already on trofinetide (Daybue)? What is the difference between the Neurogene NGN-401 intracerebroventricular approach and Taysha TSHA-102 intrathecal delivery? How would trial participation affect her therapy schedule including PT, OT, and speech? The International Rett Syndrome Foundation research portal tracks current trial opportunities.